Small Cell Lung Cancer

The AJMC® Lung Cancer compendium is a comprehensive resource for clinical news and expert insights for the condition.

Latest News

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com
Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

July 30th 2025

A retrospective analysis found whole brain radiation therapy alongside immune checkpoint inhibitors led to “brilliant” 2-year overall survival rates.

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com
Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

July 29th 2025

The findings suggest that inhibition of midkine might be a meaningful tool to improve treatment outcomes in SCLC. | Image credit: Pixel-Shot - stock.adobe.com
Midkine May Play Key Role in SCLC

July 24th 2025

Emerging therapies, including immune checkpoint inhibitors and antibody-drug conjugates, could significantly impact SCLC treatment, authors of a recent review concluded. | Image credit: Vitalii Vodolazskyi - stock.adobe.com
Is a New Era of SCLC, LCNEC Treatments on the Horizon?

July 23rd 2025

The investigators found that patients with SCLC and cachexia were more likely to have problems with treatment. | Image credit: appledesign - stock.adobe.com
Cachexia Worsens Prognosis in Older Patients With Advanced SCLC

July 9th 2025

Multidisciplinary Approaches to Paraneoplastic LEMS

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.

Hear from medical experts as they explore the connection between Lambert-Eaton myasthenic syndrome and small cell lung cancer, discussing diagnostic challenges, economic impacts, and strategies for optimizing care.
Continuing Medical Education
View All
August 26th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
August 26th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

FDA logo
January 4th 2022

CLN-081 Receives Breakthrough Therapy Designation for NSCLC

Gianna Melillo
Cullinan Oncology’s CLN-081 today received a Breakthrough Therapy Designation from the FDA for the treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC).
Site Logo
August 24th 2021

Cost-effectiveness of Nivolumab in Patients With NSCLC in the United States

Mohammad A. Chaudhary, PhD Solomon J. Lubinga, PhD Caitlin Smare, MSc Nadine Hertel, MBA John R. Penrod, PhD
This article presents a cost-effectiveness analysis of nivolumab vs docetaxel from the US payer perspective in non–small cell lung cancer (NSCLC) based on randomized phase 3 studies with a minimum 5 years of follow-up.
Diversity in a group of people.
August 1st 2021

An Inside Look at Disparities in Lung Cancer Care for At-Risk Populations

Matthew Gavidia
On World Lung Cancer Day, we explore current guidelines for lung cancer screening in the United States, implications of the COVID-19 pandemic, and disparities in mortality and access to care by race and socioeconomic status.
Kathryn Gold, MD
April 4th 2021

Insights on Small-Cell Lung Cancer NCCN Guidelines

Rose McNulty
Kathryn Gold, MD, medical oncologist and associate professor of medicine at UC San Diego, who is a member of the NCCN guidelines panel for small-cell lung cancer, gives insight into the guidelines and the importance of frequent updates.
Genomic Profiling for Mutations
February 16th 2021

FDA Approves Osimertinib for Adjuvant Treatment of Early-Stage EGFR-Mutated NSCLC

Rose McNulty
The new indication for osimertinib (Tagrisso) marks the first FDA approval of an adjuvant treatment for non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 L858R mutations.
Lung Cancer
February 16th 2021

Certain NSCLC Patients Are More Likely to Respond to Immunotherapy, Study Results Show

Rose McNulty
A recent study investigated what makes some non-small cell lung cancer patients with a type of human leukocyte antigen (HLA) called B44 are more likely than others to respond to immunotherapy.
A NSCLC tumor surrounded by metabolites involved in the hexosamine biosynthesis pathway.
February 16th 2021

Possible Treatment Identified for Aggressive NSCLC Subset

Rose McNulty
Researchers from the Children’s Medical Center Research Institute at the University of Texas Southwestern discovered a potential treatment for patients with non–small cell lung cancer (NSCLC) who have KRAS and LKB1 mutations.
Lung Cancer Screening
February 15th 2021

Lung Cancer Screenings Fall, Biopsy Rates Rise During COVID-19

Rose McNulty
Deferred low-dose computed tomography lung cancer screening during the coronavirus disease 2019 (COVID-19) pandemic has worsened outcomes for patients with lung cancer, a new study found.
FDA Grants Tiragolumab Breakthrough Therapy Designation
February 15th 2021

FDA Grants Tiragolumab Breakthrough Therapy Designation for PD-L1–High NSCLC

Rose McNulty
Genentech's tiragolumab, a novel immunotherapy for non-small cell lung cancer with PD-L1 expression, is the first anti-TIGIT therapy to be granted Breakthrough Therapy Designation.
What We’re Reading: More Americans Vaccinated Than Infected; US Funds Rapid OTC COVID-19 Tests; Breast Most Common Cancer Worldwide
February 2nd 2021

What We’re Reading: More Americans Vaccinated Than Infected; US Funds Rapid OTC COVID-19 Tests; Breast Most Common Cancer Worldwide

AJMC Staff
More Americans have received at least 1 dose of a coronavirus disease 2019 (COVID-19) vaccine than have tested positive for the virus; Biden administration funds mass production of a rapid over-the-counter COVID-19 test; breast cancer surpasses lung cancer as most common cancer worldwide.
Lungs
January 23rd 2021

First-line Nivolumab and Ipilimumab Plus Chemotherapy Improves OS in NSCLC

Rose McNulty
Recently published results show that adding a limited course of chemotherapy to nivolumab plus ipilimumab in the first-line setting for non-small cell lung cancer is effective and tolerable.
Examining Lung Scan
January 14th 2021

Study Finds No Association Between Autoimmune Disease and Lung Cancer Survival

Rose McNulty
Patients with both lung cancer and autoimmune disease have no significant difference in survival than patients with lung cancer alone, according to recent research from Northwestern University.
Doctor Looking at Scan
January 13th 2021

ACS Cancer Statistics Report Shows Record Drop in Cancer Mortality, But Persistent Disparities

Rose McNulty
The 2021 American Cancer Society annual Cancer Statistics report found that the overall rate of cancer mortality continuously declined from 1991 to 2018 but also highlighted racial and geographic disparities.
Joanna Thompson, Highlands Oncology Group
December 31st 2020

Joanna Thompson Discusses What Makes a Patient High Risk for Lung Cancer

There are several risk factors to review when determining whether or not a patient is high risk for lung cancer and should be screened, said Joanna Thompson, multidisciplinary program manager, Highlands Oncology Group.
The Top 5 Lung Cancer Stories of 2020
December 27th 2020

The Top 5 Most-Read Lung Cancer Stories of 2020

Rose McNulty
This year’s top 5 most-read stories in lung cancer were overrun by non–small cell lung cancer drug trial results and FDA action.
COVID-19 Vaccines
December 21st 2020

COVID-19 Vaccine Considerations for the Immunocompromised

Rose McNulty
FDA fact sheets on coronavirus disease 2019 (COVID-19) vaccines provide guidelines for special patient populations, including the immunocompromised.
Lung Cancer
December 17th 2020

Immunotherapy Side Effects and OS in NSCLC

Rose McNulty
NSCLC patients who developed immune-related adverse events during immunotherapy showed longer overall survival and progression-free survival than patients who did not.
Lung Health
December 11th 2020

Women Have Lower Mortality Than Men After Lung Cancer Surgery

Rose McNulty
Women had higher survival rates after lung cancer compared with men, regardless of other risk factors, in a population-based registry study from the Karolinska Instituet in Sweden.
Joanna Thompson, Highlands Oncology Group
December 10th 2020

Joanna Thompson on Engaging With PCPs for a Successful Lung Cancer Screening Program

Highlands Oncology Group has found the most success getting the word out about its lung cancer screening program by directly engaging with primary care physicians (PCPs), said Joanna Thompson of Highlands Oncology Group.
Lung Cancer
December 4th 2020

Janssen Seeks FDA Approval of Amivantamab for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations

Rose McNulty
Data from the Phase I CHRYSALIS trial also support an expanded access program that makes some patients eligible for amivantamab treatment while the FDA reviews the submission.
Drug Administration
November 25th 2020

The Importance of Cancer Clinical Trials, Even in a Pandemic

Rose McNulty
Physicians and patient advocates alike are working to spread the message that it is safe to continue on the course of cancer care and participate in clinical trials during COVID-19.
Joanna Thompson, Highlands Oncology Group
November 22nd 2020

Joanna Thompson Outlines How Highlands Oncology Group Screens for Lung Cancer

The Highlands Oncology Group partners with primary care providers to identify patients at high risk of lung cancer so the specialists can do a more in-depth screening, explained Joanna Thompson, multidisciplinary program manager, Highlands Oncology Group.
Lung Cancer
November 20th 2020

First-Line Lorlatinib Improves PFS in ALK-Positive NSCLC

Rose McNulty
Early treatment with lorlatinib led to improved progression-free survival in ALK-positive NSCLC patients compared with crizotinib treatment, a study published in the New England Journal of Medicine found.
Cost Savings at Multidisciplinary Lung Clinics
November 18th 2020

Multidisciplinary Lung Cancer Clinic Saves Patients, System Costs

Rose McNulty
Multidisciplinary lung cancer clinics might help patients and the system save on treatment costs while improving patient experiences, according to an abstract presented at CHEST 2020.
Contributor: Links Between COVID-19 Comorbidities, Mortality Detailed in FAIR Health Study
November 11th 2020

Contributor: Links Between COVID-19 Comorbidities, Mortality Detailed in FAIR Health Study

Robin Gelburd, JD
In patients under age 70, lung cancer conferred the highest risk of death from coronavirus disease 2019 (COVID-19).
Lung Cancer Screening
November 9th 2020

Lung Cancer Screening Criteria Miss Young, High-Risk Black Smokers

Rose McNulty
Current lung cancer screening guidelines do not identify high-risk young, African American smokers, an abstract presented at CHEST 2020 found.
Lung Cancer Screenings
November 4th 2020

Can Emphasis on Education Increase Lung Cancer Screenings?

Rose McNulty
Abstracts presented at CHEST 2020 explored possible reasons for low lung cancer screening rates and suggested solutions.
Lung illustration
November 3rd 2020

Libtayo Accepted for FDA Priority Review in NSCLC With PD-L1 Expression

Rose McNulty
Regeneron’s PD-1 inhibitor Libtayo was accepted for priority FDA review for the treatment of first-line locally advanced or metastatic non–small cell lung cancer (NSCLC) with PD-L1 expression of at least 50%.
Lung Cancer Screenings for Women
October 31st 2020

Lung Cancer in Women: More Risk, Less Attention

Rose McNulty
Current screening criteria in the United States identify fewer women than men who will get lung cancer, creating a perfect storm for what experts during a session at the CHEST Annual Meeting deemed an “invisible epidemic.”
Non-Small Cell Lung Cancer
October 29th 2020

KRAS G12C Inhibitor Shows Promising Effects in NSCLC, Other Solid Tumors

Rose McNulty
A pair of abstracts based on a phase 1/2 trial of adagrasib (MRTX849) a KRAS G12C inhibitor, showed promising results for patients with lung, bowel, and other solid tumors, researchers reported at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
<1
...
5678910>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo